These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21663838)

  • 1. Insulin resistance in treated HIV infection.
    Feeney ER; Mallon PW
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):443-58. PubMed ID: 21663838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance and HIV infection: a review.
    Aboud M; Elgalib A; Kulasegaram R; Peters B
    Int J Clin Pract; 2007 Mar; 61(3):463-72. PubMed ID: 17313615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.
    Dejkhamron P; Unachak K; Aurpibul L; Sirisanthana V
    J Pediatr Endocrinol Metab; 2014 May; 27(5-6):403-12. PubMed ID: 24259240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
    Samaras K
    J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
    Dubé MP
    Clin Infect Dis; 2000 Dec; 31(6):1467-75. PubMed ID: 11096014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolic puzzle during the evolution of HIV infection.
    Salas-Salvadó J; García-Lorda P
    Clin Nutr; 2001 Oct; 20(5):379-91. PubMed ID: 11534932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
    Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
    New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.
    Paik IJ; Kotler DP
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):469-78. PubMed ID: 21663840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipodystrophy and metabolic disorders in anti-HIV therapy].
    Behrens GM; Stoll M; Schmidt RE
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():68-71. PubMed ID: 10863318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy.
    Swanson B; Keithley JK; Zeller JM; Sha BE
    Nutrition; 2004; 20(11-12):1022-5. PubMed ID: 15561494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand.
    Lee B; Aurpibul L; Sirisanthana V; Mangklabruks A; Sirisanthana T; Puthanakit T
    HIV Med; 2009 Feb; 10(2):72-8. PubMed ID: 19018877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
    AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection.
    Calza L; Masetti G; Piergentili B; Trapani F; Cascavilla A; Manfredi R; Colangeli V; Viale P
    Int J STD AIDS; 2011 Jan; 22(1):43-5. PubMed ID: 21364066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.